Glenmede Trust CO Na Aerie Pharmaceuticals Inc Transaction History

Glenmede Trust CO Na

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$9.12 - $14.49 $26,028 - $41,354	-2,854 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.46 - $14.46 $1,767 - $2,443	169 Added 6.29%	2,854 $33,000
Q2 2020 Aug 14, 2020	SELL	$12.0 - $16.13 $16,068 - $21,598	-1,339 Reduced 33.28%	2,685 $39,000
Q4 2019 Feb 12, 2020	BUY	$17.72 - $25.1 $9,356 - $13,252	528 Added 15.1%	4,024 $97,000
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $13,549 - $20,608	736 Added 26.67%	3,496 $67,000

Q2 2019 Aug 13, 2019	SELL	$28.97 - $48.21 $70,107 - $116,668	-2,420 Reduced 46.72%	2,760 $81,000
Q1 2019 May 14, 2019	BUY	$36.32 - $49.25 $58,293 - $79,046	1,605 Added 44.9%	5,180 $246,000
Q4 2018 Feb 14, 2019	SELL	$33.0 - $60.04 $68,904 - $125,363	-2,088 Reduced 36.87%	3,575 $128,000
Q3 2018 Nov 15, 2018	BUY	$56.15 - $73.9 $100,340 - $132,059	1,787 Added 46.1%	5,663 $348,000
Q2 2018 Aug 15, 2018	BUY	$47.85 - $70.45 $151,301 - $222,762	3,162 Added 442.86%	3,876 $262,000
Q4 2017 Feb 15, 2018	BUY	$50.85 - $65.1 $36,306 - $46,481	714	714 $42,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.